Industry News

Search Articles:

Matinas BioPharma reports second quarter 2018 financial results
Matinas BioPharma reported a net loss attributable to common shareholders of $3.6 million, or a net loss per share basic and diluted of $0.4, compared to a net loss of $4.1 million, or a net loss per share basic and diluted of $0.4, for the same 2017 period. August 10, 2018